Dabigatran etexilate (Pradaxa®)
Last Updated: 7th August, 2013

The Effective Shared Care Agreement Toolkit (dabigatran [Pradaxa®]) was last updated on the 7th August 2013.  As a result, the content reflects the approved prescribing information (SPC) for dabigatran at that time and it has not been updated in the intervening period.  You can still access the dabigatran ESCA Toolkit but you should do so in the full knowledge that the content may not be fully up-to-date.

Successful shared care arrangements enable the combination of the best of both primary and secondary care for the benefit of the patient. They allow the seamless transfer of patient treatment from the secondary care sector to general practice. While protocols and guidelines may be useful, they in themselves do not constitute an adequate basis for shared care operations.

This Effective Shared Care Agreement Toolkit (dabigtran [Pradaxa®]) is designed to assist healthcare professionals in the development of their own shared care agreements to support locally agreed policy on the prescribing of dabigatran for the prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. In particular, it suggests ways in which responsibilities can be shared between the secondary care specialist and general practitioner (GP) / primary care prescriber. The Toolkit is intended to act as a flexible template that enables users to consider suggested content and tailor it to local circumstances and requirements.

Please note that the Effective Shared Care Agreement Toolkit is not a recommendation to prescribe dabigatran. The decision to prescribe dabigatran is the responsibility of the respective local healthcare organisation and the Toolkit should only be used after the local decision to prescribe dabigatran has been taken.

To support your local decision-making you may wish to refer to:

The Effective Shared Care Agreement Toolkit and Keele University's work in developing shared care resources has been recognised by the General Medical Council in their guidance 'Good practice in prescribing and managing medicines and devices' (January 2013).

Keele University is not responsible for the content of any linked site or manufacturer's material. Listing and linking should not be taken as an endorsement of any kind and we accept no liability in respect of the content.

Enter the
ESCA Toolkit

Agreement Library

Upload an existing agreement to the library here.


Supported by an unrestricted grant provided by Boehringer Ingelheim in the UK